title journal article pandi perumal et al i able track actual article yet even asking something could ideal antidepressant journal article title patently ridiculous medication caused remission symptoms patients minimal side effects would ideal maybe finally cured depression perhaps agomelatine really magically cure depression let take look data i found one study i could estimate treatment estimate based abstract kennedy emsley abstract said part efficacy safety flexible dosing antidepressant agomelatine mg day evaluated week double blind randomized placebo controlled study involving patients met diagnostic statistical manual mental disorders fourth edition dsm iv criteria major depressive disorder current major depressive episode patients receiving agomelatine mg mg day significantly lower mean hamilton rating scale depression ham score endpoint compared received placebo vs p based means standard deviations i come effect size considered small small effect make ideal antidepressant duplicate publication watch read abstracts two articles montgomery kennedy emsley i reproduced segment kennedy emsley abstract piece montgomery writing recent placebo controlled study mdd patients randomly assigned double blind receive placebo agomelatine mg day significant advantage agomelatine weeks according scores hamilton depression rating scale ham p clinical global impression severity p improved response rate p look familiar hype montgomery abstract closes agomelatine may fill gap current therapeutic armamentarium combining efficacy favorable tolerability profile additional clinical benefits i seen tolerability related data i see one shred data support additional clinical benefits unless referring potential improvement sleep thinking clinical benefits manner better reduction patient symptoms simply data support assertion gap current therapeutic armamentarium current treatments much effective placebo demonstrated agomelatine notable side effects ssris atypical antipsychotics emerged considered much safer better tolerated treatments predecessors know case new ideal drug better safety profile better wait see jumping yet another bandwagon treatment overly hyped way i tried find clinical trial data drug novartis website clinical trial register functional time